{"groups":[{"description":"Patients received tocilizumab (TCZ) 8 mg/kg intravenously every 4 weeks.","id":"FG000","title":"Tocilizumab 8 mg/kg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"96"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"21"}],"type":"Insufficient Therapeutic Response"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"41"}],"type":"Refused Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Failure to Return"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"538"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"355"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"183"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}